CervoMed Q1 EPS Increased by Brookline Capital Management

CervoMed Inc. (NASDAQ:CRVO) – Investment analysts at Brookline Capital Management increased their Q1 2025 EPS estimates for shares of CervoMed in a research report issued on Tuesday, March 18th. Brookline Capital Management analyst T. Bussian now anticipates that the company will earn ($0.47) per share for the quarter, up from their prior estimate of ($0.48). Brookline Capital Management currently has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Brookline Capital Management also issued estimates for CervoMed’s Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($1.75) EPS.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). The business had revenue of $2.16 million for the quarter, compared to analysts’ expectations of $1.51 million. CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%.

A number of other brokerages have also commented on CRVO. Roth Capital raised shares of CervoMed to a “strong-buy” rating in a report on Thursday, December 5th. HC Wainwright lowered shares of CervoMed from a “buy” rating to a “neutral” rating in a report on Tuesday, December 17th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of CervoMed in a report on Monday. Morgan Stanley reissued an “underweight” rating on shares of CervoMed in a report on Wednesday, December 11th. Finally, Roth Mkm raised their target price on shares of CervoMed from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, CervoMed has an average rating of “Moderate Buy” and a consensus price target of $27.50.

CervoMed Trading Up 23.4 %

Shares of CRVO stock opened at $11.56 on Thursday. The stock has a market capitalization of $71.33 million, a P/E ratio of -5.69 and a beta of 1.84. The firm’s 50 day moving average is $3.06 and its 200 day moving average is $7.90. CervoMed has a 12 month low of $1.80 and a 12 month high of $25.92.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CRVO. Citizens Financial Group Inc. RI raised its holdings in CervoMed by 13.2% in the third quarter. Citizens Financial Group Inc. RI now owns 30,509 shares of the company’s stock worth $445,000 after buying an additional 3,553 shares during the last quarter. FMR LLC purchased a new position in CervoMed in the third quarter worth about $56,000. State Street Corp raised its holdings in CervoMed by 28.1% in the third quarter. State Street Corp now owns 104,456 shares of the company’s stock worth $1,525,000 after buying an additional 22,903 shares during the last quarter. Barclays PLC grew its stake in shares of CervoMed by 323.6% in the third quarter. Barclays PLC now owns 7,748 shares of the company’s stock worth $113,000 after acquiring an additional 5,919 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of CervoMed by 13.9% in the third quarter. Geode Capital Management LLC now owns 114,934 shares of the company’s stock worth $1,678,000 after acquiring an additional 14,042 shares during the period. 25.15% of the stock is owned by hedge funds and other institutional investors.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.